Found: 24
Select item for more details and to access through your institution.
The FDA Oncology Center of Excellence and precision medicine.
- Published in:
- Experimental Biology & Medicine, 2018, v. 243, n. 3, p. 308, doi. 10.1177/1535370217740861
- By:
- Publication type:
- Article
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 11, p. N.PAG, doi. 10.1007/s11912-020-00974-z
- By:
- Publication type:
- Article
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
- Published in:
- Oncologist, 2022, v. 27, n. 6, p. 493, doi. 10.1093/oncolo/oyac042
- By:
- Publication type:
- Article
Oncology Expanded Access and FDA's Project Facilitate.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1880, doi. 10.1002/onco.13910
- By:
- Publication type:
- Article
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1786, doi. 10.1002/onco.13887
- By:
- Publication type:
- Article
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 797, doi. 10.1002/onco.13819
- By:
- Publication type:
- Article
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 5, p. 433, doi. 10.1002/onco.13752
- By:
- Publication type:
- Article
Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 318, doi. 10.1002/onco.13646
- By:
- Publication type:
- Article
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 7, p. e1077, doi. 10.1634/theoncologist.2020-0184
- By:
- Publication type:
- Article
FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. e328, doi. 10.1634/theoncologist.2019-0627
- By:
- Publication type:
- Article
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. 563, doi. 10.1634/theoncologist.2018-0084
- By:
- Publication type:
- Article
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1.
- Published in:
- Oncologist, 2019, v. 24, n. 1, p. 103, doi. 10.1634/theoncologist.2018-0221
- By:
- Publication type:
- Article
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation.
- Published in:
- Oncologist, 2018, v. 23, n. 12, p. 1520, doi. 10.1634/theoncologist.2018-0295
- By:
- Publication type:
- Article
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia.
- Published in:
- Oncologist, 2018, v. 23, n. 11, p. 1366, doi. 10.1634/theoncologist.2018-0179
- By:
- Publication type:
- Article
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations.
- Published in:
- Oncologist, 2018, v. 23, n. 6, p. 740, doi. 10.1634/theoncologist.2017-0642
- By:
- Publication type:
- Article
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
- Published in:
- Oncologist, 2018, v. 23, n. 6, p. 734, doi. 10.1634/theoncologist.2017-0440
- By:
- Publication type:
- Article
Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
- Published in:
- Oncologist, 2018, v. 23, n. 4, p. 496, doi. 10.1634/theoncologist.2017-0422
- By:
- Publication type:
- Article
FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
- Published in:
- Oncologist, 2018, v. 23, n. 3, p. 353, doi. 10.1634/theoncologist.2017-0425
- By:
- Publication type:
- Article
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- Editorial
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
- Published in:
- Oncologist, 2017, v. 22, n. 11, p. 1392, doi. 10.1634/theoncologist.2017-0078
- By:
- Publication type:
- Article
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
- Published in:
- Oncologist, 2017, v. 22, n. 11, p. 1347, doi. 10.1634/theoncologist.2017-0229
- By:
- Publication type:
- Article
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
- Published in:
- Oncologist, 2017, v. 22, n. 7, p. 873, doi. 10.1634/theoncologist.2016-0496
- By:
- Publication type:
- Article
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.
- Published in:
- Oncologist, 2017, v. 22, n. 7, p. 762, doi. 10.1634/theoncologist.2017-0152
- By:
- Publication type:
- Article
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
- Published in:
- Oncologist, 2017, v. 22, n. 6, p. 743, doi. 10.1634/theoncologist.2017-0087
- By:
- Publication type:
- Article